Advances in clinical and safety studies of phosphodiesterase 4 inhibitors
10.16438/j.0513-4870.2022-1401
- VernacularTitle:磷酸二酯酶4抑制剂临床及安全性研究进展
- Author:
Hui-fang WANG
;
You-zhi WANG
;
Yun-bao ZHI
;
Lin-fei ZUO
;
Hui-zhen SHEN
;
Zheng-wen XU
;
Jin-xin WANG
- Publication Type:Research Article
- Keywords:
phosphodiesterase;
phosphodiesterase 4 inhibitor;
clinical efficacy;
safety;
side effect
- From:
Acta Pharmaceutica Sinica
2023;57(9):2601-2609
- CountryChina
- Language:Chinese
-
Abstract:
Phosphodiesterase 4 (PDE4) is an important member of the phosphodiesterase enzyme family that specifically catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP), activates the downstream phosphorylation cascade pathway by altering cAMP concentration, and is strongly associated with multiple diseases. Inhibition of PDE4 is clinically investigated as a therapeutic strategy in a broad range of disease areas, including respiratory system diseases, autoimmune disorders, central nervous system diseases, and dermatological conditions. However, the incidence of adverse reactions such as nausea and vomiting is relatively high in the marketed PDE4 inhibitors, which has stalled their clinical development. In this review, we provide an overview of the clinical progression and safety issues of the marketed PDE4 inhibitors. We also review the main causes underlying PDE4-mediated adverse effects by combining the structural analysis of the PDE4 protein, the mechanism of action of PDE4 inhibitors, and the related side effect mechanism research, aiming to provide a reference for the development of safe and effective PDE4 inhibitors.
